Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice

Dagmar Wertaschnigg*, Maya Reddy, Ben W.J. Mol, Fabricio Da Silva Costa, Daniel L. Rolnik

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)
2 Downloads (Pure)


In this review, we discuss the recent literature regarding the prevention of preeclampsia and aim to answer common questions that arise in the routine antenatal care of pregnant women. Prescription of low-dose aspirin for high-risk patients has been shown to reduce the risk of preeclampsia (PE). A daily dose between 100 and 150 mg taken in the evening should be initiated prior to 16 weeks of gestation and can be continued until delivery. Calcium supplementation seems to be advantageous but currently it is only considered for patients with poor dietary intake and high risk for PE. Recent data about heparin are still conflicting, and therefore, heparin can currently not be recommended in the prevention of PE.

Original languageEnglish
Article number2675101
JournalJournal of Pregnancy
Publication statusPublished - 1 Aug 2019

Bibliographical note

Acknowledgments Dagmar Wertaschnigg is supported by a grant from the Paracelsus Medical University Salzburg, Austria [PMU Research Fund–PMU FFF Number: L-18/02/006-WET], and by Drs Haackert Foundation, Germany.


Dive into the research topics of 'Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice'. Together they form a unique fingerprint.

Cite this